NOVATEK PHARMACEUTICALS
NP-101
Enhances your IMMUNE SYSTEM & inflammatory response
NP-101 is derived from a natural product N.Sativa with therapeutic potential in management of SARS-CoV-2 due to its anti-viral activity. Derived from Nigella Sativa plant, it has been extensively studied and shown to possess a wide spectrum of activities which include antibacterial, antifungal and antiviral effects among many others.
Near term milestones include completion of a Phase 2 clinical study to support possible FDA Emergency Use Authorization to treat non-hospitalized SARS-CoV-2 positive patients with mild to moderate COVID-19 infection with corresponding symptoms.
Based on NIH guidelines there are five categories of COVID-19 disease severity. The least severe category designation is “Non-hospitalized, Mid to Moderate COVID-19” Treatment summary for this category of patients “Insufficient data to recommend for/against any specific antiviral or antibody therapy. SARS-CoV-2 neutralizing antibodies (bamlanivimab or casirivimab plus imdevimab) are available through EUAs for out-patients at high risk of disease progression.
NP-101 is the only current orally-administered treatment targeted to this COVID-19 patient category. Novatek Pharmaceutical was created to develop and commercialize an innovative therapeutic approach to treat Cancer and COVID-19. In other words, our product was driven by wanting to provide effective results to offer great health benefits with quality that lives up to the highest standards.
N sativa ( Core component of NP-101 ), due to its wide range of bioactive components, could offer a range of benefits for treating COVID-19, such as blocking the introduction of the virus to pneumocytes; providing ionophores to improve zinc intake, thereby improving the host immune response to SARS-CoV-2; and preventing the virus from replicating. N Sativa has been found to confer a range of therapeutic advantages including antioxidant, anti-inflammatory, anticancer, antibacterial, antifungal, anticoagulant, anti-sepsis, and anticonvulsant activity. N Sativa seeds have also demonstrated immunomodulatory effects, while several studies suggest that N Sativa seeds have some antiviral effects. In addition to its immunomodulatory and antioxidant properties, however, N Sativa and its active constituents have also been noted to provide anti-ischemic effects in several organs, including the brain, kidney, heart, liver, and intestines. Such evidence strongly suggests that N. sativa seeds and their active constituents may have significant therapeutic potential against COVID-19 and its complication. Novatek Pharmaceuticals bring their expertise in pharmacology, oncology, and clinical research in order to develop and commercialize an innovative therapeutic approach to treat COVID-19.
N.Sativa may block the SARS-CoV-2 entry via ACE2 in pneumocytes. N. sativa oil produce antinociceptive effects through indirect activation of supraspinal μ1- and κ-opioid receptor subtypes. In addition, brain endogenous angiotensin II is involved in central nociceptive mechanisms by its antagonistic interaction with the endogenous opioid system. It has been shown that opioid active peptides such as hemorphins have inhibitory effect on ACE. This line of evidence suggests that opioid receptors and ACE share similar inhibitory molecules; and, as such, it is possible that N.Sativa might also block ACE2.